Sun Pharmaceutical Industries Ltd.
-
NSE: SUNPHARMA
-
BSE: 524715
-
Q
-
V
-
T
Quality Score
High Financial StrengthValuation Score
Mid ValuationTechnical Score
Technically NeutralBroker average target upside %
11.00 %
Below industry Median
TTM PE Ratio
28.30
Above industry Median
Price to Book Ratio
4.00
Below industry Median
Operating Revenues Qtr Cr
10930.70 Cr
Market Leader
Net Profit Qtr Cr
1984.50 Cr
Market Leader
RSI
64.10
RSI is mid-range
MFI
67.00
MFI is mid-range
MACD
2.70
MACD above Signal and Center
MACD Signal Line
-4.40
MACD above Signal and Center
30Day SMA Rs
962.10 Rs
Price above SMA 962.07
50Day SMA Rs
973.20 Rs
Price above SMA 973.16
100Day SMA Rs
986.50 Rs
Price above SMA 986.46
200Day SMA Rs
975.90 Rs
Price above SMA 975.90
Promoter holding %
54.48
No change in Promoter holding
FII holding current Qtr %
16.88
FII holdings rise by 0.01%
MF holding current Qtr %
12.91
MF holdings rise by 0.45%
Institutions holding %
36.12
Institutions holding increased by 0.1100%.
Broker Average Rating
4.80
Broker Average Rating
Broker Covering stock
11.00
11 Broker Covering stock
Broker 1Year total
28.00
28 Broker 1Year total
Broker 6M Reco downgrade
0.00
0 Broker 6M Reco downgrade
Broker 6M Reco upgrade
2.00
2 Broker 6M Reco upgrade
Broker 6M Target downgrade
8.00
8 Broker 6M Target downgrade
Broker 6M Target upgrade
4.00
4 Broker 6M Target upgrade
Momentum score
52.66
Technically Neutral
Valuation score
35.33
Mid Valuation
Quality score
75.06
High Financial Strength
-
- 2023-05-31T08:56:24+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q4 FY23 Earnings Call Transcript
Read More -
- 2023-05-30T16:51:58+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to requirement of Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2022-23.
Read More -
- 2023-05-30T13:38:21+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting
Read More -
- 2023-05-30T11:47:14+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to 'Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque Psoriasis', which we shall be releasing after sending this letter to you. This submission is being made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Read More -
- 2023-05-30T05:04:04+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to 'Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY(tm) in Europe, Australia and New Zealand', which we shall be releasing after sending this letter to you. This submission is being made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Read More -
- 2023-05-27T17:05:32+00:00
Sun Pharmaceutical Industries Results Earnings Call for Q4FY23
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Read More -
- 2023-05-27T06:16:41+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting
Read More -
- 2023-05-26T21:26:33+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Non-Binding Indication Of Interest To Acquire Shares Of Taro Pharmaceutical Industries Ltd., Israel
On May 26, 2023, Sun Pharmaceutical Industries Limited ('Company') has issued a letter to the Board of Directors of Taro Pharmaceutical Industries Ltd., Israel ('Taro') with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares in Taro, other than any shares already held by the Company or its affiliates (For a purchase price of $38 per ordinary share, in cash the 'Proposal'). Copy of the letter containing the Proposal is enclosed herewith as Annexure A. This disclosure is being submitted pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Read More -
- 2023-05-26T21:14:18+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Appointment Of Directors
The Board of Directors at their meeting held on May 26, 2023, inter alia, have approved the following: 1. Appointment of Mr. Rolf Hoffmann as an Independent Director 2. Appointment of Mr. Aalok Shanghvi as a Whole-time Director
Read More -
- 2023-05-26T20:55:24+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Update
In connection with our earnings call held on May 26, 2023, we wish to update that Global Ilumya sales for FY23 were US$ 477 million, up by about 51% as compared to FY22.
Read More -
- 2023-05-26T16:16:03+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Q4FY23 Investor Call Audio Recording
Q4FY23 Investor call audio recording
Read More -
- 2023-05-26T16:02:12+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the disclosure of related party transactions for the half year ended March 31, 2023 is enclosed herewith.
Read More -
- 2023-05-26T10:25:45+00:00
Q4FY23 Quarterly & FY23 Annual Result Announced for Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries announced Q4FY23 & FY23 results: Q4FY23: Gross sales at Rs 1,07,256 million, growth of 14.3% vs Q4 last year India formulation sales at Rs 33,641 million, up 8.7% vs Q4 last year US formulation sales at US$ 430 million, up 10.5% vs Q4 last year Global specialty sales at US$ 244 million, including US$ 6.8 million milestone received in Q4. Ex-milestone, up 28% vs Q4 last year Global specialty sales, ex-milestone, accounted for 18.2% of Q4FY23 overall sales Emerging Markets formulation sales at US$ 221 million, up 7.5% vs Q4 last year Rest of World formulation sales at US$ 191 million, up 7.4% vs Q4 last year R&D investments at Rs 6,657 million compared to Rs 5,433 million for Q4 last year EBITDA at Rs 28,021 million, up 19.7% vs Q4 last year. EBITDA margin for Q4 at 25.6% vs 24.8% for Q4 last year. Reported net profit for Q4FY23 was Rs 19,845 million compared to net loss Rs 22,773 mn for Q4 last year. Excluding the exceptional items, adjusted net profit for Q4FY23 was Rs 21,559 million, up 36.3% over Q4 last year. FY23: Gross sales at Rs 4,32,789 million, growth of 12.6% over same period last year India formulation sales at Rs 1,36,031 million, up 6.6% over same period last year US formulation sales at US$ 1,684 million, up 10.3% over same period last year Global specialty sales at US$ 871 million, up 29% over same period last year Emerging Markets formulation sales at US$ 983 million, up 8.6% over same period last year Rest of World formulation sales at US$ 752 million, up 2.7% over same period last year R&D investments at Rs 23,676 million compared to Rs 22,194 million for FY22 EBITDA at Rs 1,16,468 million up 12% over same period last year. EBITDA margin for FY23 at 26.5% vs 26.9% for same period last year. Reported net profit for FY23 was Rs 84,736 million compared to Rs 32,727 million for FY22 Excluding the exceptional items, adjusted net profit for FY23 was Rs 86,450 million, up 12.8% over same period last year Dilip Shanghvi, Managing Director of the Company said, “I am pleased with well-rounded growth demonstrated in FY23 by the company. Several of our businesses including Specialty, India and Emerging markets have continued to progress well. Our Specialty business remains on growth path and we are committed to continue scaling it up. Acquisition of Concert helps further strengthen our portfolio in dermatology. I believe deuruxolitinib can become a leading product to address highly unmet need in alopecia areata patients.” Result PDF
Read More -
- 2023-05-26T09:34:14+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Financial results for the fourth quarter ending March 31th, 2023.
Read More -
- 2023-05-26T09:20:00+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corporate Action-Board approves Dividend
With reference to the intimation of Board meeting submitted on May 11, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. May 26, 2023 which commenced at 10:40 a.m. and ended at 02:35 p.m., wherein the Board has, inter-alia, Recommended Final Dividend for financial year 2022-23 Final dividend of Rs. 4.00/- (Rupees Four only) per equity share of Re. l/- (Rupee One only) each of the Company is recommended subject to approval of the shareholders at the ensuing 31st Annual General Meeting and which shall be paid within the timelines as required under the Companies Act, 2013.
Read More -
- 2023-05-26T09:17:52+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Results For The Quarter And Year Ended March 31, 2023
With reference to the intimation of Board meeting submitted on May 11, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. May 26, 2023 which commenced at 10:40 a.m. and ended at 02:35 p.m., wherein the Board has, inter-alia, 1. Approved Financial Results for the fourth quarter and year ended March 31, 2023 2. Recommended Final Dividend for financial year 2022-23
Read More -
- 2023-05-25T10:46:44+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Read More -
- 2023-05-24T12:39:58+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 24, 2023 for Raksha Sudhir Valia
Read More -
- 2023-05-12T13:20:54+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Read More -
- 2023-05-11T11:50:20+00:00
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Press Release relating to Earnings Call for financial results for the fourth quarter and full year ending March 31, 2023.
Read More
| Ex-date | Dividend Amount | Dividend Type | Record Date |
|---|
Bonus History
Adani Ports & Special Economic Zone Ltd. has not announced any bonus since Jan 1, 2000.
Check out stocks with top dividendAdani Ports & Special Economic Zone Ltd. has split the face value 1 time since Sept. 23, 2010. Adani Ports & Special Economic Zone Ltd. had last split the face value of its shares from Rs 10 to Rs 2 in 2016.The share has been quoting on an ex-split basis from Sept. 23, 2010.
| Ex-date | Old FV | New FV | Record Date |
|---|---|---|---|
| Sept. 23, 2010 | 10 | FINAL | Sept. 24, 2010 |